IDH inhibitors alone and in combination with other drugs have not been significantly more effective than other current therapies (e.g. venetoclax-based drug regimen) in the treatment of newly diagnosed AML patients with IDH mutations. The gene discussed is IDH2; the disease is acute myeloid leukemia.